When a company cuts prices on its flagship product, it's usually not because things are going great. And when that company is Novo Nordisk, which just watched its next-generation obesity drug crash and burn in clinical trials, the 50% price cut on Wegovy looks less like strategy and more like desperation.

The Danish pharmaceutical giant announced Tuesday it's slashing Wegovy list prices by 50% and Ozempic prices by up to 40%. This came exactly one day after CagriSema—the drug that was supposed to close the gap with rival Eli Lilly's Zepbound—missed its primary endpoint in a head-to-head trial. Translation: their best shot at keeping up with the competition just failed.

Novo is now down 60% from its 2024 peak. Copenhagen shares are trading at their lowest levels since June 2021. CEO Lars Fruergaard Jørgensen stepped down. Seven analysts downgraded the stock in two days. This is not what a healthy turnaround looks like.

Here's the thing about desperate price cuts: they rarely work when you're cutting prices on your main growth driver. I went back through a decade of major corporate price cuts—30% or more under pressure—and found 12 cases across pharma, tech, auto, and consumer sectors. Roughly half recovered. Half didn't.

The companies that bounced back had one thing in common: the product being cut wasn't their primary growth engine. Eli Lilly slashed insulin prices 70% in March 2023—the biggest percentage cut on the list. The stock went up that day and finished 2023 up 59%. Why? Because insulin was maybe 10% of Lilly's revenue and shrinking. The real money was in Mounjaro and Zepbound, which were just getting started. Lilly sacrificed a declining product, earned political goodwill, and rode the GLP-1 wave.

Novo's situation is the opposite. Wegovy and Ozempic represent roughly 70% of the company's growth. CagriSema was supposed to be the next generation. Now it's gone, and they're cutting prices on the drugs that actually make money while Lilly gains prescriptions in the same market.

The closest comparison isn't Lilly. It's Gilead Sciences. Gilead's hepatitis C drugs—Sovaldi and Harvoni—were blockbusters, pulling in $19 billion at peak. Then AbbVie launched a cheaper competitor, Express Scripts dropped Harvoni from its formulary, and Congress investigated the pricing. Gilead responded with steep rebates—40% to 60% effective net price cuts over two years. Revenue collapsed from $19.1 billion to $3.7 billion over four years. The stock lost 29% in 2016 and didn't recover to 2015 highs for five years.

The problem was structural: the drug cured the disease, which meant every treated patient was a permanently lost customer. Novo doesn't have that exact problem, but they do have a problem where their main product is now competing on price rather than efficacy.

So what does this mean for investors? If you're holding Novo, you're betting that price cuts will expand the market enough to offset the margin compression. That's possible—cheaper Wegovy could bring in millions of patients who were priced out. But you're also betting against Lilly, which has the better drug and isn't cutting prices.

If you're thinking about buying the dip, remember that Mylan cut EpiPen prices and the stock never recovered. Peloton cut bike prices and went from $170 to under $5. When the product being cut is the growth driver and there's no replacement ready, the dip usually keeps dipping.

Novo needs a new drug, not a sale. Until they have one, this is a falling knife.